ReviewAnnals of hematology2026
In mantle cell lymphoma, whether 18 F-FDG PET/CT or flow cytometry provide superior diagnostic performance compared to biopsy in the determination of bone marrow involvement and enhance prognostic predictive value.
Review in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate whether 18 F-FDG Positron Emission Tomography/Computed Tomography (PET/CT) and Flow Cytometry (FCM) can serve as alternatives to bone marrow biopsy (BMB) in diagnosing bone marrow involvement (BMI), prognostic prediction, and clinical application of mantle cell lymphoma (MCL). This retrospective analysis was conducted to assess the impact of PET/CT, FCM, and BMB results on BMI in 122 patients diagnosed with MCL who underwent PET/CT and bone marrow examinations, and 97 patients with complete survival data were included in the survival analysis. Taking BMB positive as the standard, the sensitivity of PET/CT was 57.4% (31/54), with a specificity of 55.9% (38/68). The positive predictive value (PPV) was 50.8% (31/61), while the negative predictive value (NPV) was 62.3% (38/61). A ratio of lymphoma cells exceeding 5.925% was defined as FCM positive (Supplemental Fig. 1), the sensitivity of FCM increased to 90.7% (49/54), and specificity was 77.9% (53/68). The PPV was 76.6% (49/64), and the NPV reached 91.4% (53/58). Multivariate analysis indicated that age, a MIPI score of 6 or higher, and morphological variants are independent prognostic factors for progression-free survival (PFS) and overall survival (OS) (all P < 0.05). The ratio of lymphoma cells ≥ 30% is an independent prognostic factor for PFS (P < 0.05). The PET/CT high-risk group showed lower PFS and OS than the control group, even though not an independent prognostic factor. The PFS prediction model incorporated the above independent prognostic factors and demonstrated excellent prognostic predictive value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.